New blood test detects 90% of aggressive prostate cancer cases, beating current screenings

Stockholm3 blood test detected 90% of aggressive prostate cancer cases compared to 74% for PSA tests in a study of over ...

New blood test detects aggressive prostate cancer more accurately than PSA, study finds

A new study suggests the investigational Stockholm3 blood test may improve the early detection of aggressive prostate cancer ...
Morningstar

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use

Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use Tempus AI, Inc., a leader in ...

UF Health Cancer develops prostate cancer urine test

According to the institute, a single, reliable test to differentiate aggressive, life-threatening cancers from slower-growing ...
Hosted on MSN

Tempus AI expands cancer platform with launch of ArteraAI prostate test for metastatic patients

・Tempus AI is expanding its clinical oncology offering with the launch of ArteraAI Prostate Test for metastatic hormone-sensitive prostate cancer. ・The tool combines digital pathology and genomic ...
Medscape

AI Test Predicts Abiraterone Benefit in Localized High-Risk Prostate Cancer

A multimodal AI model identified a subset of men with very high-risk localized prostate cancer who derived substantial ...

Tempus AI Expands Precision Oncology With New Prostate Test And ASCO Data

Tempus AI (NasdaqGS:TEM) has launched the ArteraAI Prostate Test, its first externally developed AI-powered digital pathology test for metastatic hormone-sensitive prostate cancer. The test is ...

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

Detailed price information for Myriad Genetics Inc (MYGN-Q) from The Globe and Mail including charting and trades.
Business Insider

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

SALT LAKE CITY, May 26, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test ...